Tecentriq combo leads to median OS of 18.1 months at interim analysis of Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy did not show a significant improvement on the co-primary endpoint of overall survival (OS) compared with chemotherapy alone at an interim analysis of the Phase III IMpower132 trial to treat stage IV non-squamous non-small cell lung cancer (NSCLC). Data were presented at the World Conference on Lung Cancer in Toronto.

At the interim analysis, Tecentriq plus chemotherapy led to a median OS of 18.1 months vs. 13.6 months for chemotherapy alone (HR=0.81, 95% CI: 0.64, 1.03, p=0.0797). The Tecentriq combo led to median progression-free survival (PFS) of 7.6 months vs. 5.2 months for chemotherapy alone (HR=0.6, 95% CI: 0.49, 0.72, p<0.0001). Additionally, Tecentriq plus chemotherapy led to an objective response rate (ORR) of 47% with a median duration of response of 10.1 months vs. an ORR of 32% with a median duration of response of 7.2 months for chemotherapy alone...